BDSX Insider Purchase: Jack Schuler Adds 142K Shares

Rhea-AI Filing Summary

Jack W. Schuler, a director and greater-than-10% owner of Biodesix, purchased 142,045 shares of Biodesix Inc. (BDSX) on 09/19/2025 at a price of $7.04 per share. After the purchase, Mr. Schuler beneficially owns 1,380,745 shares indirectly through the Jack W. Schuler Living Trust and holds an additional 750,000 shares indirectly via the Jack W. Schuler 2025 GRAT. The Form 4 was signed by an attorney-in-fact on 09/23/2025. The filing shows no derivative transactions and indicates Mr. Schuler is sole trustee of both the Living Trust and the 2025 GRAT.

Positive

• Insider purchase of 142,045 shares at market price, indicating a direct acquisition by a director/10% owner
• Clear beneficial ownership reporting: total indirect holdings disclosed (1,380,745 via Living Trust; 750,000 via 2025 GRAT)
• No derivative transactions reported, reducing complexity in ownership picture

Negative

• None.

Insights

Securities Analyst

TL;DR: A meaningful insider purchase: director/10% owner bought 142,045 shares at $7.04, increasing his indirect stake.

This Form 4 reports a non-derivative acquisition by Jack W. Schuler, who serves as a director and is identified as a >10% owner. The purchase of 142,045 shares at $7.04 increases his beneficial holdings to 1,380,745 shares via his living trust, with an additional 750,000 shares held in a GRAT. Insider purchases by large shareholders or directors can signal confidence in the company’s near-term prospects, particularly when executed through trusts rather than options or derivatives. The filing contains no sales, no option exercises, and no other compensatory or derivative trades to complicate the ownership picture.

Corporate Governance Expert

TL;DR: Director/trustee increased indirect ownership through a straightforward open-market purchase; governance structure is clarified in disclosures.

The disclosure specifies Mr. Schuler as sole trustee of both the Living Trust and the 2025 GRAT, clarifying the nature of indirect ownership. The transaction is coded as a purchase (P) and reported in a timely manner. There are no indications of related-party transfers or derivative instruments in this filing. From a governance perspective, the clear identification of trust structures and timely reporting align with Section 16 transparency expectations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHULER JACK W

(Last) (First) (Middle)

PO BOX 531

(Street)

LAKE BLUFF IL 60044

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		P		142,045	A	$7.04	1,380,745	I	By Jack W. Schuler Living Trust(1)
Common Stock								750,000	I	By Jack W. Schuler 2025 GRAT(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

2. Jack W. Schuler is the sole trustee of the Jack W. Schuler 2025 GRAT.

	/s/ Robin H. Cowie as Attorney-in-Fact for Jack Schuler	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the Form 4 for BDSX report?

The Form 4 reports a purchase of 142,045 shares of Biodesix (BDSX) on 09/19/2025 at $7.04 per share.

How many Biodesix shares does Jack W. Schuler beneficially own after the transaction?

He beneficially owns 1,380,745 shares indirectly via his Living Trust and additionally 750,000 shares via the Jack W. Schuler 2025 GRAT.

What is Jack W. Schuler’s relationship to Biodesix?

The form identifies him as a Director and a greater-than-10% owner of Biodesix.

Were any derivative securities reported on this Form 4?

No. Table II shows no derivative transactions; only a non-derivative purchase is reported in Table I.

Who signed the Form 4 filing?

The Form 4 was signed by /s/ Robin H. Cowie as Attorney-in-Fact for Jack Schuler on 09/23/2025.